| ACLF |
Acute on Chronic Liver Failure |
| AI |
Artificia intelligence |
| ALTAI |
the Assessment List for Trustworthy Artificial Intelligence |
| AP-HP |
Assistance Publique-Hôpitaux de Paris |
| ARFI |
Acoustic radiation force impulse |
| CA |
Consortium Agreement |
| CAGR |
Compound Annual Growth Rate |
| CBM |
Centre-based models |
| CDM |
Common data model |
| CDSS |
Clinical decision support system |
| CLD |
Chronic liver disease |
| CE mark |
Conformité Européenne mark |
| CFD |
Computational Fluid Dynamics |
| CPMG |
Carr-Purcell-Meiboom-Gill |
| CPU |
Central Processing Unit |
| CT |
Computed Tomography |
| CVD |
Cardiovascular disease |
| DCM |
Deformable Cell Model |
| DL |
Deep learning |
| DM |
Diabetes Mellitus |
| DMP |
Data Management Plan |
| DPO |
Data Protection Officer |
| eCRF |
Electronic Case Report Form |
| EASL |
European Association for the Study of the Liver |
| EC |
European Commission |
| ECM |
Extra-Cellular Matrix |
| ECOG |
Eastern Cooperative Oncology Group |
| EHDS |
European Health Data Space |
| EHR |
Electronic Health Report |
| EIA |
Ethics Impact Assessment |
| ETL |
Extract-Transform-Load |
| FAIR |
Findability, Accessibility, Interoperability and Reusability |
| FL |
Federated Learning |
| FDA |
Food and Drug Administration |
| GA |
Grant Agreement |
| GDPR |
The General Data Protection Regulation |
| GPU |
Graphics Processing Unit |
| HBV |
Hepatitis B virus |
| HCC |
Hepatocellular carcinomas |
| HCV |
Hepatitis C virus |
| HeTran-BL |
Hemodynamics and transport at whole body level |
| HeTran-OL |
Hemodynamics and transport at the organ level |
| HeTran-TL |
Hemodynamics and transport at the tissue level |
| HF |
Heart Failure |
| HGF |
Hepatocyte growth factor |
| HIS |
Hospital Information System |
| HIV |
Human immunodeficiency virus |
| HPC |
High Performance Cloud |
| HRS-1 |
Hepatorenal syndrome type 1 |
| HSC |
Hepatic stellate cells |
| HTA |
Health technology assessment |
| HVPG |
Hepatic venous pressure gradient |
| ICI |
Immune checkpoint inhibitor(s) |
| IL |
Interleukin |
| INF |
Interferon |
| IP |
Intellectual Property |
| IT |
Information Technology |
| JUH |
Jena University Hospital |
| KER |
Key exploitable results |
| KOL |
Key opinion leaders |
| KRCO |
Key Relevant Clinical Outputs |
| L-VT |
Liver virtual twin |
| MACE |
Major Adverse Cardiac Events |
| MASLD |
Metabolic-associated fatty liver disease |
| MDR |
Medical Device Regulation |
| MELD |
Model for End-Stage Liver Disease |
| ML |
Machine Learning |
| MR-elastography |
Magnetic Resonance elastography |
| MRI |
Magnetic Resonance Imaging |
| MVP |
Minimum viable product |
| My-VT |
heart Myocardial Virtual Twin |
| NAFLD |
Nonalcoholic fatty liver disease |
| NASH |
Nonalcoholic steatohepatitis |
| NLP |
Natural language processing |
| NMR |
Nuclear Magnetic Resonance |
| ODE |
Ordinary Differential Equations |
| OHIF |
Open Health Imaging Foundation |
| ORE |
Open research europe |
| PACS |
Picture Archiving and Communication System |
| PCB |
Project coordination board |
| PCSB |
Project Clinical Study Board |
| PDE |
Partial Differential Equations |
| PHES |
Psychometric Hepatic Encephalopathy Score |
| POC |
Proof of concept |
| SBML |
Systems Biology Markup Language |
| SCORE |
Systemic Coronary Risk Estimation |
| SME |
Small and middle enterprises |
| SSH |
Social Sciences and Humanities |
| SOTA |
State-of-the-art |
| SW |
Software |
| T2DM |
Type 2 Diabetes Mellitus |
| TACE |
Trans-arterial chemoembolization |
| TGF |
Transforming growth factor |
| TKI |
Tyrosine kinase inhibitors |
| TIPS |
Transjugular intrahepatic portosystemic shunt |
| UKHD |
Universitat Klinikum Heidelberg |
| VCTE |
Vibration controlled transient elastography |
| VT |
Virtual Twin |
| VVUQ |
Verification, Validation, and Uncertainty Quantification |
